Neobiosis Appoints Pascal Goldschmidt, M.D. as Chief Medical Officer
UF Innovate | Sid Martin Biotech resident Neobiosis, a clinical-stage contract development and manufacturing organization, managed by scientists and physicians and focused on the science of regenerative medicine, announced the appointment of Pascal Goldschmidt, M.D. as Chief Medical Officer.
As CMO Dr. Goldschmidt will oversee the clinical translation of Neobiosis’ regenerative products through Investigational New Drug (IND) applications with the FDA and into clinical trials. Dr. Goldschmidt is an accomplished cardiologist, professor, academic healthcare leader, and medical researcher. He has served as a Tenured Professor at three prestigious institutions, Duke University School of Medicine, Ohio State University (OSU) and University of Miami. He was Center Director at Johns Hopkins University School of Medicine, Chief of Cardiology at OSU, then at Duke, and Chairman of Medicine at Duke. In 2006, he became Dean of the Miller School of Medicine and Founder/CEO of UHealth, the University of Miami Health System.
Learn more about Neobiosis Appoints Pascal Goldschmidt, M.D. as Chief Medical Officer.